Overview

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combining 3-AP with gemcitabine in treating patients who have refractory metastatic breast cancer. Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining 3-AP with gemcitabine may kill more tumor cells
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Gemcitabine